Newsmeme!
Discover News you didn't know existed
LONDON, Feb 9 (Reuters) - A British court has upheld a ruling invalidating a patent on a gene sequence held by Human Genome Sciences, handing victory in the case to Eli Lilly which had challenged HGS's patent, lawyers familiar with the case said on Tuesday. The ruling could affect future decisions by UK courts on the scope of biotech patents, they said, and may also influence decisions in other ...
Researchers suggest that a prion-like protein may participate in memory in higher eukaryotes.
Researchers report in the Feb. 8 issue of the journal Pediatrics that using a standard 1-inch needle to immunize obese adolescents against hepatitis B virus produces a much weaker effect than using a longer needle.Amy B.
HIGH WYCOMBE, England, February 8 /PRNewswire/ -- STELARA (ustekinumab) has today been accepted by the Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland for the treatment of moderate to severe plaque psoriasis.(1) STELARA is the first in a novel class of biologics.
MONROVIA, Calif.----Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today the appointment of Edgardo Baracchini, Ph.D., to chief business officer.
Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.
Compugen Ltd. today reported financial results for the fourth quarter and year ending December 31, 2009.
Novavax, Inc. (Nasdaq: NVAX) announced new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax's trivalent seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine matched the influenza strains recommended for the 2008-2009 influenza season including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006 strains...
GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, provided an update on its vaccine trials progress. "The HIV/AIDS population continues to grow at an alarming rate, 60,000 new infections annually, and that's just in the United ...
Immunovaccine Inc. (TSX VENTURE:IMV) announced that it has been invited to present at the Canada - U.S. Partners in Biomedical Defense II Conference in Washington, D.C. on Wednesday, February 10, 2010. At the Conference the Company will present positive new research, done in collaboration with Defence Research and Development Canada (DRDC), confirming the number of required doses for an anthrax ...
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |